Table 3.
Similar studies of relationship between SUVmax and EGFR mutation status in NSCLC
| Author | N | Histology | Stage | EGFR mutation | Lesions Measured | Favor factor in mutation |
|---|---|---|---|---|---|---|
| Lee et al. 11 | 71 | ADC | IV | 48 (68%) | pSUVmax; nSUVmax; SUVmax | Low nSUVmax; mSUVmax |
| Huang et al. 12 | 77 | ADC | III-IV | 49 (64%) | pSUVmax | High pSUVmax |
| Qiang et al. 13 | 97 | ADC | I-III | 44 (45%) | pSUVmax | Low pSUVmax |
| Li et al. 14 | 115 | ADC, | I-IV | 64 (56%) | pSUVmax | Low pSUVmax |
| Minamimoto et al. 15 | 131 | ADC | I-IV | 32 (24%) | pSUVmax | Low pSUVmax |
| Ko et al. 16 | 132 | ADC | I-IV | 69 (52%) | pSUVmax | High pSUVmax |
| Zhu et al. 17 | 139 | ADC | I-IV | 74 (53%) | pSUVmax | Low pSUVmax |
| Yang et al. 18 | 200 | ADC | I-IV | 115 (58%) | pSUVmax | Low pSUVmax |
| Gu et al. 19 | 210 | ADC, non-ADC | I-IV | 70 (33%) | pSUVmax | Low pSUVmax |
| Guan et al. 20 | 316 | ADC, non-ADC | I-IV | 126 (40%) | pSUVmax | Low pSUVmax |
| Yip et al. 21 | 348 | ADC, non-ADC | I-IV | 44 (13%) | pSUVmax | Low pSUVmax |
| Kazuya et al. 22 | 734 | ADC | I-IV | 334 (46%) | pSUVmax | Low pSUVmax |
| Lv et al. 8 | 849 | ADC, non-ADC | I-IV | 371 (46%) | pSUVmax; nSUVmax; mSUVmax | Low pSUVmax; nSUVmax; mSUVmax |
ADC: adenocarcinoma; pSUVmax: SUVmax in primary tumor; nSUVmax: SUVmax in regional lymph node; mSUVmax: SUVmax in distant metastasis.